Search details
1.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Lancet
; 401(10373): 269-280, 2023 01 28.
Article
in English
| MEDLINE | ID: mdl-36709073
2.
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Eur J Haematol
; 112(3): 379-391, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37899734
3.
A potentially new thromboembolic event scoring system in polycythaemia vera patients: An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia register.
Eur J Haematol
; 111(2): 263-270, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37203365
4.
Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.
Int J Mol Sci
; 24(6)2023 Mar 18.
Article
in English
| MEDLINE | ID: mdl-36982875
5.
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Blood
; 135(12): 912-920, 2020 03 19.
Article
in English
| MEDLINE | ID: mdl-31978221
6.
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Future Oncol
; 18(7): 755-769, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-35139644
7.
Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
Br J Haematol
; 194(2): 355-364, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34019713
8.
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Lancet
; 395(10232): 1278-1291, 2020 04 18.
Article
in English
| MEDLINE | ID: mdl-32305093
9.
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Future Oncol
; 17(12): 1449-1458, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33423550
10.
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Future Oncol
; 17(11): 1295-1310, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33528286
11.
Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.
Eur J Haematol
; 105(4): 408-418, 2020 Oct.
Article
in English
| MEDLINE | ID: mdl-32557810
12.
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Am J Hematol
; 95(2): 178-187, 2020 02.
Article
in English
| MEDLINE | ID: mdl-31821591
13.
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.
Haematologica
; 109(2): 676-681, 2024 Feb 01.
Article
in English
| MEDLINE | ID: mdl-37259556
14.
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Health Qual Life Outcomes
; 17(1): 173, 2019 Nov 15.
Article
in English
| MEDLINE | ID: mdl-31729982
15.
Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis.
Haematologica
; 108(7): 1960-1964, 2023 Jul 01.
Article
in English
| MEDLINE | ID: mdl-36601980
16.
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.
Ann Hematol
; 97(9): 1591-1600, 2018 Sep.
Article
in English
| MEDLINE | ID: mdl-29804268
17.
Recommendations for the diagnosis and treatment of patients with polycythaemia vera.
Eur J Haematol
; 2018 Jul 30.
Article
in English
| MEDLINE | ID: mdl-30058088
18.
[Pernicious anemia in a thalassemic patient - difficulties of the diagnosis]. / Thalassaemiás betegen észlelt anaemia perniciosa a diagnózis nehézségei.
Orv Hetil
; 159(33): 1368-1371, 2018 Aug.
Article
in Hungarian
| MEDLINE | ID: mdl-30099903
19.
[Hungarian clinical application opportunities of PET/MR imaging and first experiences]. / A PET/MR képalkotás magyarországi klinikai alkalmazásának lehetoségei, elso tapasztalatai.
Orv Hetil
; 159(34): 1375-1384, 2018 Aug.
Article
in Hungarian
| MEDLINE | ID: mdl-30122057
20.
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
Lancet Oncol
; 18(1): 88-99, 2017 01.
Article
in English
| MEDLINE | ID: mdl-27916398